Verification Opinion
1. Basic Situation of Raised Funds
Huatai United Securities Co., Ltd. (hereinafter referred to as "Huatai United Securities" or "Sponsor") is the sponsor for Hualan Biological Engineering Co., Ltd. (hereinafter referred to as "Hualan Vaccine" or "Company") during its initial public offering and continuous supervision phase. In accordance with the "Regulations on the Management of Securities Issuance and Listing Sponsorship Business," "Regulations on the Supervision of Raised Funds of Listed Companies," "Shenzhen Stock Exchange Growth Enterprise Market Listing Rules," and "Self-Regulatory Guidelines No. 2 for Listed Companies on the Shenzhen Stock Exchange - Standardized Operations of Growth Enterprise Market Listed Companies," Huatai United Securities conducted a prudent due diligence investigation on Hualan Vaccine's plan to continue using part of the idle raised funds for cash management. The specific situation is as follows:
According to the China Securities Regulatory Commission's approval (Zheng Jian Xu Ke [2022] No. 2), Hualan Vaccine was authorized to publicly issue 40,010,000 shares of RMB ordinary shares (A shares), with a par value of RMB 1 per share and an issuance price of RMB 56.88 per share, raising a total of RMB 2,275,768,800.00. After deducting various issuance expenses of RMB 31,565,696.07 (including tax), the actual net raised funds amounted to RMB 2,244,203,103.93. The raised funds were transferred to Hualan Vaccine's designated account on February 14, 2022. Hualan Vaccine signed a "Tripartite Supervision Agreement on Special Accounts for Raised Funds" with the sponsor and the bank holding the raised funds to jointly supervise the use of the raised funds. Dahua Certified Public Accountants (Special General Partnership) conducted a verification of the funds on February 14, 2022, and issued a "Verification Report" (Dahua Yan Zi [2022] No. 000066).
2. Use of Raised Funds
According to the "Prospectus for Hualan Biological Engineering Co., Ltd.'s Initial Public Offering and Listing on the Growth Enterprise Market" (hereinafter referred to as "Prospectus"), the plan for the use of raised funds is as follows:
| No. | Project | Total Committed Investment | Adjusted Investment Amount |
|---|---|---|---|
| 1 | Influenza Vaccine Development and Industrialization and Existing Product Supply Assurance Project (Completed) | 108,426.42 | 80,107.90 |
| 2 | Development and Industrialization of Freeze-Dried Human Rabies Vaccine | 8,600.00 | 7,735.45 |
| 3 | Development and Industrialization of Multivalent Bacterial Vaccine | 27,425.00 | 24,667.97 |
| 4 | Development and Industrialization of New Pneumonia Vaccine (Before Change) | 76,080.81 | 33,901.04 |
| 5 | New Vaccine R&D Platform Construction Project | 28,970.51 | 26,058.11 |
| 6 | Development and Industrialization of Recombinant Shingles Vaccine (After Change) | — | 56,421.08 |
| Total | 249,502.74 | 228,891.55 |